Drug recall · January 1, 2025
chlorproMAZINE Hydrochloride Tablets recall
Why: CGMP Deviations: N-Nitroso-Desmethyl Chlorpromazine impurity (NNDCI) were found to be failing per current FDA recommended limit.
Class II: could cause temporary or reversible health problems; serious harm is remote.
The recall
- Product
chlorproMAZINE Hydrochloride Tablets, USP, 10mg, 100-count bottle, RX only, Manufactured for: Glenmark Pharmaceuticals Inc., NJ; Product of India, NDC 68462-861-01
- Lots / codes
Lot#: 17230132, Exp 12/2024; 17230449, Exp 01/2025
- Quantity
- 3,888
- Company
- Glenmark Pharmaceuticals Inc., USA, Mahwah, NJ
- Distribution
- USA Nationwide
- Initiated
- December 11, 2024 · Voluntary: Firm initiated
- Classified
- December 23, 2024
- Reported
- January 1, 2025
- How notified
- Letter
The drug: prices, other makers, shortages
If you have this product
- Check the lot number on your package against the lots above. Only those lots are recalled.
- Don't stop a prescription medicine on your own. Call your pharmacy - they can swap it for an unaffected lot or another maker.
- Felt unwell? Contact your doctor, and report it to FDA MedWatch (1-800-FDA-1088 or fda.gov/medwatch).
- Return or dispose of recalled product as the company or your pharmacy advises.
Recalled with it (same recall event)
Questions about this recall
No comments yet. Questions, tips, what worked for you - start the conversation.
Watch Chlorpromazine
One email when the price moves, a recall or shortage is posted, or the label changes. Plus the monthly biggest-movers report. Unsubscribe in one click.